Year |
Citation |
Score |
2019 |
Balakrishnan A, Rajan A, Salter AI, Kosasih PL, Wu Q, Voutsinas J, Jensen MC, Plückthun A, Riddell S. Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548346 DOI: 10.1158/1078-0432.Ccr-19-1479 |
0.537 |
|
2019 |
Specht J, Lee S, Turtle C, Berger C, Balakrishnan A, Srivastava S, Viollet V, Veatch J, Gooley T, Mullane E, Chaney C, Rader C, Pierce R, Gottardo R, Maloney D, et al. Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-09-13 |
0.497 |
|
2018 |
Balakrishnan A. CAR-T Cells: Next Generation Cancer Therapeutics Journal of the Indian Institute of Science. 98: 21-31. DOI: 10.1007/S41745-018-0062-8 |
0.557 |
|
2017 |
Balakrishnan A, Salter AI, Plückthun A, Riddell SR. Abstract A75: Designed Ankyrin Repeat Proteins (DARPins) as recognition motifs in chimeric antigen receptors Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A75 |
0.53 |
|
2016 |
Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter P, Riddell SR. Analysis of ROR1 protein expression in human cancer and normal tissues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852699 DOI: 10.1158/1078-0432.Ccr-16-2083 |
0.503 |
|
2015 |
Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research. 3: 206-16. PMID 25355068 DOI: 10.1158/2326-6066.Cir-14-0163 |
0.561 |
|
2014 |
Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer Journal (Sudbury, Mass.). 20: 141-4. PMID 24667960 DOI: 10.1097/Ppo.0000000000000036 |
0.483 |
|
2014 |
Berger SC, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paskiewicz P, Kosasih P, Rader C, Riddell S. Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P3 |
0.59 |
|
2013 |
Balakrishnan A, Chaillet JR. Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas. Developmental Biology. 373: 118-29. PMID 23078915 DOI: 10.1016/J.Ydbio.2012.10.011 |
0.358 |
|
Low-probability matches (unlikely to be authored by this person) |
2009 |
Balakrishnan A, Cirio MC, Chaillet JR. Role of the Tgkd Transgene in the Development of Ovarian Teratomas. Biology of Reproduction. 81: 318-318. DOI: 10.1093/Biolreprod/81.S1.318 |
0.216 |
|
2014 |
Balakrishnan A, Chaillet JR. DNA is not the whole story: Transgenerational epigenesis and imprinting Textbook of Human Reproductive Genetics. 68-82. DOI: 10.1017/CBO9781139236027.006 |
0.087 |
|
Hide low-probability matches. |